CSIMarket Company Name, Ticker, Suppliers, else..
 
Opus Genetics Inc   (NASDAQ: IRD)
 
Price: $3.6200 $-0.07 -1.897%
Day's High: $3.7200000286102295 Week Perf: -11.92 %
Day's Low: $ 3.51 30 Day Perf: -2.43 %
Volume (M): 574,900 52 Wk High: $ 5.81
Volume (M$): $ 0 52 Wk Avg: $3.27
Open: $3.71 52 Wk Low: $1.22



 Market Capitalization (Millions $) 315
 Shares Outstanding (Millions) 87
 Employees 28
 Revenues (TTM) (Millions $) 12
 Net Income (TTM) (Millions $) -107
 Cash Flow (TTM) (Millions $) 18
 Capital Exp. (TTM) (Millions $) 0

Business Description


Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies for inherited retinal diseases and other ophthalmic disorders. Its pipeline includes gene therapies targeting specific genetic mutations responsible for retinal degeneration, as well as a small-molecule therapy for eye conditions. The company conducts clinical trials to assess the safety and efficacy of its treatments, including OPGx-LCA5 for Leber congenital amaurosis type 5.


   Company Address: 8 Davis Drive Durham 27713 NC
   Company Phone Number: 884-6030   Stock Exchange / Ticker: NASDAQ IRD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -2.5%    
ALKS   -4.41%    
BMRN   -0.98%    
LLY   -5.21%    
MDGL        5.48% 
SUPN   -2%    
• View Complete Report
   



Clinical Study

Opus Genetics Doses First Participant in Phase 1/2 Clinical Trial for Best Disease Gene Therapy,

Published Thu, Nov 13 2025 12:34 PM UTC

In a pioneering move in the field of ophthalmic gene therapy, Opus Genetics has achieved a significant milestone by dosing the first participant in its OPGx-BEST1 Phase 1/2 clinical trial aimed at treating Best Disease, a rare inherited retinal disorder. This landmark occasion not only sets the stage for potential breakthroughs in the treatment of this debilitating condition...
Clinical Study

Opus Genetics Unveils Promising Phase 3 Results for Phentolamine Ophthalmic Solution at World Cornea Congress...

Published Fri, Mar 21 2025 4:47 PM UTC

RESEARCH TRIANGLE PARK, N.C. March 21, 2025 In a noteworthy advancement in the realm of ophthalmic medicine, Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company that specializes in the development of gene therapies for inherited retinal diseases (IRDs) and other ophthalmic disorders, has announced the presentation of significant findings from the L...
Clinical Study

Longitudinal Efficacy of OPGx-LCA5 in Adults with Leber Congenital Amaurosis Insights from the Phase 1/2 Trial Presen...

Published Mon, Mar 10 2025 12:00 PM UTC

The field of ocular gene therapies has seen significant advancements in recent years, particularly for retinopathies such as Leber Congenital Amaurosis (LCA), a severe inherited retinal dystrophy. Opus Genetics has unveiled promising preliminary findings from their ongoing Phase 1/2 trial of OPGx-LCA5, a novel gene therapy targeting patients with LCA caused by mutations in t...
Clinical Study

A Visionary Approach APX3330s Journey in Transforming Diabetic Retinopathy Treatment,

Published Thu, Dec 19 2024 1:00 PM UTC

Exploring the Journey of APX3330 in Diabetic Retinopathy: A New Horizon in Ophthalmic Treatment Diabetic retinopathy is a prevalent microvascular complication of diabetes, often leading to vision impairment or loss. Treatment options have remained limited, necessitating continuous exploration into novel therapies. Opus Genetics achieves a significant milestone with FDA s S...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 26.25
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 6.42
Working Capital Ratio 7.13
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -1.39 $
Revenues (TTM) 0.14 $
Cash Flow (TTM) 0.21 $
Cash 0.69 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 427,964
Net Income per Employee (TTM) -3,819,000
Receivable Turnover Ratio (TTM) 4.77
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.25

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -665.92 %
Net Margin (MRQ) -3038.25 %
Net Cash Flow Margin (MRQ) 689.29 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Opus Genetics Inc's Segments
Viatris License Agreement    101.99 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.